Exploring the Capital, Development and Real Estate Strategies Shaping the Region’s Biotech Ecosystem

Greater Philadelphia’s life sciences market is entering a more selective and consequential phase. CBRE reported that two major leases totaling more than 360K SF represented all of the region’s life sciences leasing during Q1 2026, while newly available inventory contributed to occupancy losses. At the same time, early-year funding activity offered a potential signal that investor confidence may be beginning to improve.

The region is also attracting investments that extend its economy beyond research and into company formation, specialized production and commercial-scale manufacturing. Johnson & Johnson announced plans to invest more than $1B in a Montgomery County cell therapy facility expected to support 500 permanent biomanufacturing jobs, Legend Biotech opened a 31K SF Philadelphia R&D center, and Penn, BioNTech and Osage University Partners launched a $50M fund for early-stage companies spun out of Penn.

These contrasting forces are creating important decisions for owners, developers, investors and occupiers. Where is demand actually emerging? Which properties can compete for today’s tenants? What will it take for companies to remain and expand in the region? And how can Greater Philadelphia convert its scientific discoveries into sustained real estate demand, investment and job growth?